Robert Zeiser, MD, discusses the landscape of graft versus host disease and reviews data related to the current treatment options.
EP. 1: GVHD Pathophysiology
Robert Zeiser, MD, reviews the pathophysiology of graft versus host disease and explains its relationship to the desired graft versus leukemia effect.
EP. 2: Differences Between Acute and Chronic GVHD and Risk Factors for GVHD
Dr Zeiser outlines the differences between acute and chronic GVHD and also reviews factors that put transplant patients at greater risk of GVHD.
EP. 3: GVHD Prophylaxis and Patient Presentation
Selection of prophylaxis regimen is reviewed followed by a discussion of the typical patient presentation of GVHD.
EP. 4: Chronic GVHD First-Line Therapy
A GVHD expert comments on the frontline therapy available for the condition.
EP. 5: Treatments for Steroid-Refractory cGVHD
Therapies for steroid-refractory chronic graft-vs-host disease, ibrutinib, ruxolitinib, and belumosudil, are explored in a comprehensive analysis.
EP. 6: Additional Therapy Options for Steroid-Refractory cGVHD
Robert Zeiser, MD, touches on additional therapeutic options for steroid-refractory chronic graft-vs-host-disease, such as extracorporeal photopheresis, mycophenolate, everolimus, and more.
EP. 7: Adverse Events From cGVHD Therapies
Adverse events related to chronic graft-vs-host-disease therapies and strategies to manage these adverse effects are considered.
EP. 8: Future Directions for GVHD
Closing out the program, Robert Zeiser, MD, shares what he is looking forward to in the field of graft-vs-host-disease.
2 Clarke Drive Cranbury, NJ 08512